Remo CRO

News

FDA Grants Rare Pediatric Disease Designation to Pegzilarginase for Arginase 1 Deficiency

10.04 2018.

AUSTIN, Texas, Oct. 01, 2018 (GLOBE NEWSWIRE) — Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer,… Details

New cancer vaccine may tackle HER2-positive tumors

10.02 2018.

A new cancer vaccine shows promise for treating a range of more aggressive HER2-positive cancers in an early, phase I clinical trial. Details

Drug resistance: 'Trojan horse' compound kills bacteria from within

10.02 2018.

Researchers have found a way to ‘trick’ bacteria into eating a compound that is similar to iron and destroys the microbes from the inside. Details

Genentech’s Investigational Medicine Entrectinib Showed a Durable Response of More Than Two Years in People With a Specific Type of Lung Cancer

09.27 2018.

South San Francisco, CA — September 24, 2018 — Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results for its investigational medicine entrectinib, from an integrated analysis of the pivotal Phase II… Details

GSK candidate vaccine helps prevent active pulmonary tuberculosis in HIV negative adults in phase II study

09.27 2018.

London 25 September 2018 — Today, GSK and Aeras reported that GSK’s M72/AS01E[1] candidate vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults with latent tuberculosis infection[2] in an ongoing… Details

Pfizer Granted FDA Breakthrough Therapy Designation for 20-Valent Pneumococcal Conjugate Vaccine for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older

09.27 2018.

September 20, 2018 — Pfizer Inc. (NYSE:PFE) announced today that its 20-Valent Pneumococcal Conjugate Vaccine (20vPnC) candidate, PF-06482077, received Breakthrough Therapy1 designation from the US Food and Drug Administration (FDA) for the… Details